We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+11.92%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$303M
AUM Growth
+$48M
Cap. Flow
+$31.8M
Cap. Flow %
10.49%
Top 10 Hldgs %
45.97%
Holding
88
New
25
Increased
24
Reduced
13
Closed
14

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$13M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$8.63M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$6.27M
4
CYTK icon
Cytokinetics
CYTK
+$5.46M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$4.84M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.7M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.34M
3
ESTA icon
Establishment Labs
ESTA
+$5.32M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$5.05M
5
NARI
Inari Medical, Inc. Common Stock
NARI
+$4.2M

Sector Composition

Rank Sector Weight
1 Healthcare 79.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$22.6M 7.46%
976,021
+157,986
+19% +$3.77M
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$12.8B
$22.5M 7.44%
93,000
+23,000
+33% +$6.27M
SPY icon
3
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$18.4M 6.08%
+45,000
New +$18M
RXDX
4
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$16.1M 5.31%
150,000
+75,000
+100% +$8.63M
MRK icon
5
Merck
MRK
$315B
$12.8M 4.21%
+120,000
New +$13M
VKTX icon
6
Viking Therapeutics
VKTX
$4.31B
$10.4M 3.42%
622,249
+272,249
+78% +$2.81M
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$9.44M 3.12%
1,083,118
-60,413
-5% -$484K
CERE
8
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$9.27M 3.06%
380,000
+165,000
+77% +$4.84M
VRNA
9
DELISTED
Verona Pharma
VRNA
$9.09M 3%
452,821
+140,323
+45% +$3.03M
VTYX
10
DELISTED
Ventyx Biosciences
VTYX
$8.71M 2.87%
260,008
+19,385
+8% +$754K
CYTK icon
11
Cytokinetics
CYTK
$10.9B
$7.79M 2.57%
221,463
+133,862
+153% +$5.46M
ESTA icon
12
Establishment Labs
ESTA
$2.72B
$7.67M 2.53%
113,224
-77,543
-41% -$5.32M
ATXS
13
DELISTED
Astria Therapeutics
ATXS
$7.04M 2.32%
529,369
+56,887
+12% +$769K
BBIO icon
14
PUT
BridgeBio Pharma
BBIO
$15.9B
$6.46M 2.13%
+389,800
New +$4.55M
BLU
15
DELISTED
BELLUS Health Inc.
BLU
$6.35M 2.09%
881,329
+307,651
+54% +$2.39M
ACLX
16
DELISTED
Arcellx
ACLX
$6.25M 2.06%
202,834
-37,309
-16% -$1.13M
MRNA icon
17
CALL
Moderna
MRNA
$24.5B
$5.38M 1.77%
+35,000
New +$5.77M
BBIO icon
18
BridgeBio Pharma
BBIO
$15.9B
$5.31M 1.75%
+320,000
New +$3.73M
MORF
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$5.11M 1.69%
135,863
-145,058
-52% -$5.34M
KURA icon
20
Kura Oncology
KURA
$964M
$4.37M 1.44%
357,287
+88,540
+33% +$1.1M
INZY
21
DELISTED
Inozyme Pharma
INZY
$4.31M 1.42%
751,796
+251,796
+50% +$665K
ASND icon
22
Ascendis Pharma A/S
ASND
$17.1B
$4.29M 1.42%
40,000
-30,997
-44% -$3.55M
AZN icon
23
AstraZeneca
AZN
$262B
$4.16M 1.37%
30,000
– –
SGEN
24
DELISTED
Seagen Inc. Common Stock
SGEN
$4.05M 1.34%
20,000
+15,000
+300% +$2.41M
ARGX icon
25
argenx
ARGX
$53.8B
$4.01M 1.32%
10,750
+5,750
+115% +$2.13M
1
2 3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Affinity Asset Advisors held 88 positions worth $303M, up 19% from $255M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Affinity Asset Advisors deployed $31.8M of net new capital in Q1 2023, opening 25 new positions and adding to 24 existing holdings. Its largest new stake was Merck: 120,000 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 81% a quarter earlier.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $5.7M trimmed.

  • Affinity Asset Advisors's largest Q1 2023 buy was Merck: 120,000 shares worth $12.8M.
  • Affinity Asset Advisors added most to Prometheus Biosciences, Inc. Common Stock in Q1 2023, an estimated $8.63M increase.
  • Affinity Asset Advisors's biggest Q1 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $5.7M.
  • Affinity Asset Advisors fully exited Rocket Pharmaceuticals in Q1 2023, selling an estimated $5.05M.
  • Affinity Asset Advisors's ten largest holdings make up 46% of its $303M portfolio in Q1 2023.
  • Affinity Asset Advisors opened 25 new positions and closed 14 in Q1 2023.
  • Affinity Asset Advisors's portfolio value rose 19% quarter-over-quarter to $303M.

Based on Affinity Asset Advisors's 13F filing for Q1 2023, filed 15 May 2023.